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Abstract
Introduction/Aims: Aerobic deconditioning, due to lower levels of physical activity,
could impact independence for people with neuromuscular conditions. We report the
maximal cardiopulmonary response in a cohort of people with Charcot Marie Tooth
disease type 1A (CMT 1A) and inclusion body myositis (IBM). We also explored
potential predictors of aerobic capacity with measures of physical impairment and
functional performance.
Methods: Participants underwent maximal cardiopulmonary exercise testing (CPET)
using a semi-recumbent cycle ergometer. Data were analyzed to determine the peak
O2 consumption (VO2 peak), anaerobic threshold (AT), maximum heart rate (MHR),
ventilatory equivalent for CO2 slope (VE/VCO2), and respiratory exchange ratio
(RER). Impairment, functional and patient reported measures were also recorded.
Predicted CPET variables were calculated based on published normative data for age,
gender, and weight.
Results: Twenty-two people with CMT and 17 people with IBM were recruited. Both
groups showed significantly lower VO2 peak, MHR, AT, and VE/VCO2. The CMT
group overall performed better than the IBM group, with significantly higher VO2
peak, MHR, and AT, but lower VE/VCO2. Linear regression analysis demonstrated
that VO2 peak was related to body fat percentage and 6-min walk distance for both
groups, and steps per day for the IBM group.
Discussion: Lower than predicted CPET variables were observed that were not
explained by cardiopulmonary limitations or reduced effort, implicating peripheral
factors in limiting the cycling task. Regression analysis implied prediction of VO2
peak by body fat percentage and 6-min walk distance. Six-minute walk distance could
be a potential proxy measure of cardiopulmonary fitness.
Abbreviations: 10MTW, 10 meter timed walk; AT, anaerobic threshold; BMI, body mass index; BP, blood pressure; CMT, Charcot Marie Tooth disease; CMT 1A, Charcot Marie Tooth disease
type 1A; CMTESv2, CMT Examination Score version 2; CPET, cardiopulmonary exercise testing; FVC, forced vital capacity; IBM, inclusion body myositis; IBMFRS, Inclusion Body Myositis
Functional Rating Scale; IPAQ, International Physical Activity Scale; MHR, maximum heart rate; NMD, neuromuscular disease; P-P plots, normally probability plots; RER, respiratory exchange
ratio; SBP, systolic blood pressure; VAS, Visual Analogue Scale; VE/VCO2, ventilatory equivalent for CO2 slope; VO2 peak, peak O2 consumption.
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1 | INTRODUCTION
People with neuromuscular diseases (NMDs) may be at increased
risk of morbidities such as obesity, cardiovascular, and metabolic
conditions,1 because of lower levels of physical activity.2,3 Insufficient
physical activity is a major risk factor for the development of non-
communicable diseases, with an associated 20%–30% increased risk
of all-cause mortality.4 Low aerobic capacity can negatively impact on
independent community living. Aerobic de-conditioning and second-
ary disuse muscle atrophy are common in people with NMD and are a
likely consequence of reduced general activity levels. Investigations of
people with Charcot Marie Tooth disease (CMT) found they are less
active than the general population2,3,5 and are “de-conditioned,” as
measured by oxygen uptake during exercise.6 Similar reductions in
aerobic capacity have been reported in people with idiopathic inflam-
matory myopathy,7 but this has not been explored in inclusion body
myositis (IBM).
The objective of this study was to undertake detailed measure-
ment of the cardiopulmonary response during maximal cycling exer-
cise in large cohorts of adult patients with two neuromuscular
diseases: CMT type 1A (CMT 1A) and sporadic IBM. We anticipated
that both disease groups would have lower than predicted aerobic
capacity when compared to normative data; however, we also aimed
to explore body structure, impairment and functional factors that
relate to aerobic capacity. This would allow us to understand if there
are factors that can be targeted with rehabilitation, and whether there
are proxy measures that may indicate aerobic capacity without com-
plex, laboratory measurement procedures.
2 | METHODS
Potential participants were recruited as a convenience sample from
clinics and research databases of the National Hospital for Neurology
and Neurosurgery, plus national clinics of colleagues from the British
Myology Society over a 26-mo period. All participants were recruits
on an aerobic exercise training intervention trial,8 and here we present
an analysis of the baseline data This study achieved NHS NRES ethical
approval (ref: 11/LO/0760) and consent for participation was
obtained. The main trial was registered on the ISRCTN clinical trials
registry (ID: 99826269).
Participants were included in the study if they met the following
criteria: clinical and genetic diagnosis of CMT1A, or a clinical diagnosis
of IBM, supported by histological confirmation as per the established
Griggs criteria (only Griggs definite IBM cases were included9); aged
18–80 y; able to walk for 30 m with or without a walking aid or
orthotic devices; able to safely mount/dismount an exercise bike with
minimal assistance.
Exclusion criteria were: presence of other significant neurological
disorders or major co-morbidities; limb surgery during the 6 mo prior
to screening (or planned before final assessment); failure to pass the
screening assessment for exercise testing; concurrent involvement in
another intervention trial; people already participating in moderate
(3–5.9 times the intensity of rest) to vigorous (six or more times the
intensity of rest)10 aerobic exercise more than three times per week;
women of child-bearing age if they were pregnant.
In total, 282 people with CMT 1A were invited to participate in the
main intervention trial8 and 254 were excluded, refused or did not
respond. The most common reasons for active exclusion were co-existing
illness or recent limb surgery; already exercising over 3 days per week;
unable to meet time commitments; did not meet the more detailed
screening criteria. In total, 122 people with IBM were invited to partici-
pate and 102 were unable to commit to the trial or did not meet the study
criteria on initial screening. The most common reasons were too old for
the age criteria; did not want to participate; co-existing illness.
Study subjects with CMT 1A and IBM underwent cardiopulmonary
exercise testing (CPET) in accordance with American Thoracic Society/
American College of Chest Physicians.11 A screening algorithm was used,
prior to maximal exercise testing, that included details of medical history,
physical examination and electrocardiogram (ECG) findings. Participants
performed a single symptom-limited, incremental ramp protocol to voli-
tional exhaustion using a semi-recumbent electromagnetically braked
cycle ergometer (Lode Corival, Groningan, Netherlands). During the test
on-line gas exchange analysis, ECG monitoring, and arterial blood pres-
sure were measured with a Cortex MetaLyzerII® (Biophysik, Leipzig,
Germany). ECG and blood pressure (BP) were monitored before, during,
and after the test. Tests were considered suitable for inclusion if it was
judged that the participant gave a maximal effort and reached their phys-
iologic limitation as per the American Thoracic Society/American College
of Chest Physicians statement on Cardiopulmonary Exercise Testing.10
Other tests were excluded if technical or practical difficulties stopped
the test early (e.g., unable to get a clear BP or ECG reading, or the partici-
pant was unable to keep their foot on the bike pedal due to straps having
loosened). This ensured that all data included in this analysis were true
maximal test data.
CPET data only were analyzed by an experienced exercise physiolo-
gist (co-author P.H.) to determine the peak O2 consumption (VO2 peak)
normalized to body weight, anaerobic threshold (AT) using the modified
v-slope method,12 maximum heart rate and ventilatory equivalent for CO2
slope (VE/VCO2). AT is the physiological point during exercise at which
lactic acid starts to accumulate in the muscles, which occurs around the
point during increasing intensity exercise that anaerobic processes become
more dominant. The VE/VCO2 slope reflects the increase in ventilation in
response to CO2 production, and thus shows increased ventilatory drive.
The peak respiratory exchange ratio (RER) is an indicator of exercise exer-
tion level. It is defined as carbon dioxide production divided by oxygen
consumption, and a peak RER equal to or more than 1.10 indicates maxi-
mal exercise effort.13 The exercise physiologist only had access to the
CPET data and not additional demographic and clinical data.
Other variables recorded were age, sex, and disease severity;
version 2 of the CMT Examination Score (CMTESv2) was recorded by
a neurologist for CMT participants14 and Inclusion Body Myositis
Functional Rating Scale (IBMFRS) for IBM participants.15 Body struc-
ture and impairment measures were recorded: body mass index, body
fat percentage using skinfold callipers, waist circumference, forced
vital capacity (FVC), resting heart rate, blood pressure, isokinetic peak
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torque of the knee flexors and extensors at 60/s (Cybex HUMAC
dynamometer). After a minimum of 1 h of rest, measures of functional
activity included: 10 m timed walk (10MTW), 6-min walk; and 7 days
of physical activity monitoring using a multi-sensor wearable device
(Sensewear Activity Monitor). The 6-min walk was the final functional
measure to maximize the time following the exercise testing. Partici-
pant reported outcome measures captured some of the non-motoric
symptoms and perceptions: Fatigue Severity Scale,16 Walk-12,17
Visual Analogue Scale (VAS) for pain, International Physical Activity
Scale (IPAQ),18 barriers to activity and exercise.19
3 | ANALYSIS
Predicted CPET variables were calculated based on published norma-
tive data for age, gender and weight.20-22 Comparing the actual with
predicted values between the groups accounted for potential con-
founds of age, gender, and weight.
Normally probability plots (P-P plots) of the CPET data were
drawn and indicated that the data were normally distributed.
Unpaired t-test were used to compare CPET variables between the
disease groups, ascertain differences between CPET variables and
predicted values and explore disease group differences in continuous
secondary outcomes. Categorical secondary outcomes were com-
pared between disease groups using a Wilcoxon rank sum test.
Linear regression modeling was used to explore potential associa-
tions with VO2 peak for each disease group (Stata, version 15, UK).
Two models were explored: body structure and physical impairment
variables associated withVO2 peak and functional performance pre-
dictors of VO2 peak. First, an exploratory correlation analysis was
undertaken with individual variables. A modified Bonferroni correction
was used account for multiple comparisons23: 15 variables for model
1 and 7 variables for model 2. Variables that reached significance fol-
lowing correction were then entered into a multiple linear regression
model. A stepwise method was used to remove the variables that
showed the weakest associations. Weak associations were defined as
TABLE 1 Demographic, disease severity, body structure and impairment measures, and functional activity outcomes
Group CMT IBM P-Value
Demographics N 22 17
Age (y) 43.8 ± 14.5 61.5 ± 10.08 >.0001
Sex (male/female) 9 female, 13 male 4 female, 13 male
Disease severity scales CMTES 10 (8–12)
IBMFRS 28 (24–31)
Body structure and impairments Body mass index (kg/m2) 27.70 ± 3.49 26.08 ± 3.77 .154
Waist/hip ratio 0.89 ± 0.09 0.95 ± 0.11 .099
Body fat % 25.45 ± 5.69 24.27 ± 4.78 .503
Forced vital capacity in sitting (L) 3.28 ± 0.85 2.88 ± 0.91 .172
Resting heart rate (beats/min) 67.64 ± 7.89 68.13 ± 8.91 .895
SBP (mmHg) 121.68 ± 15.70 131.13 ± 13.22 .037
Diastolic blood pressure (mmHg) 77.73 ± 6.21 78.69 ± 5.49 0.699
Peak isokinetic knee extensor torque (nm) 85.25 ± 41.93 23 ± 23.74 >.0001
Peak isokinetic knee flexor torque (nm) 46.16 ± 19.18 24.18 ± 19.16 .0011
Fatigue severity scale 32 (20–40) 29 (22–46) .681
Visual analogue scale for pain 2 (0.9–4.5) 1 (0–2) .117
Functional activities 10 meter timed walk (s) 17.09 ± 3.19 22.58 ± 7.10 .0026
6-min walk (m) 378.81 ± 79.12 292.03 ± 87.85 .0025
Total daily energy expenditure (calories) 2613.28 ± 463.40 2356.18 ± 487.15 .101
Average steps per day 8214 ± 3965 4732 ± 2840 .0041
Average METs per day 1.432 ± 0.189 1.306 ± 1.187 .067
Physical activity duration per day (min) 120.14 ± 64.36 85.65 ± 71.20 .122
Sedentary time (min) 1151.14 ± 242.03 1281.18 ± 146.58 .059
Walk-12 34.5 (31–41) 42 (36–49) .055
IPAQ sitting time (min/day) 378 ± 183.58 388 ± 177.63 .871
Falls self-efficacy scale 41 (33.3–50.0) 42 (36–49) .379
Note: Continuous data are expressed as the group mean ± standard deviation and categorical data as the group median and interquartile range. Continuous
P values are shown following inferential testing.
Abbreviation: METs, metabolic equivalent.
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having non-significant p-values (above .05) and a correlation coeffi-
cient below .2.
4 | RESULTS
Twenty-two people with CMT and 17 people with IBM were rec-
ruited to the study. The IBM group was older with a smaller propor-
tion of females and slightly higher systolic blood pressure (SBP), but
there were no other differences between disease groups in demo-
graphics and general health measures (Table 1).
4.1 | CPET performance
Comparisons with normative data demonstrated that the CMT partici-
pants had significantly lower CPET performance for all variables
(Table 2). In the IBM group, the same was true for all variables except
for VE/VCO2 slope. There was a highly significant difference in per-
centage predicted AT and percentage predicted VO2 peak (Table 2),
with the IBM group performing worse (Figure 1).
Participants with CMT performed significantly better than the IBM
group when comparing the actual values, with the exception of maximum
ventilation and RER (Table 2). No differences between the groups were
observed for maximum heart rate and ventilatory efficiency (VE/VCO2)
slope. RER was 1.10 and above for both groups indicating patients in both
groups were working at high intensities at exercise cessation (Table 2).
4.2 | Differences in body structure and
impairment, activity, and patient reported outcomes
Body structure and impairment measures were comparable between
groups, with the exception of higher SBP for the IBM group (Table 1).
TABLE 2 CPET variables for the CMT and IBM groups















Max heart rate (bpm) 134.2 ± 17.7 176.2 ± 14.5 >.0001 121.4 ± 13.9 158.5 ± 10.1 >.0001 .019
Anaerobic threshold (ml/kg/min) 12.1 ± 2.1 15.4 ± 2.2 >.0001 8.35 ± 2.3 14.8 ± 2.3 >.0001 >.0001
VO2 peak (ml/kg/min) 21.6 ± 4.6 28 ± 5.2 .0001 14.3 ± 3.1 25.6 ± 4.81 >.0001 >.0001
VE/VCO2 slope 25.3 ± 2.5 26.6 ± 1.6 .0423 27.6 ± 3.1 28.1 ± 1.4 .559 .0117
Max ventilation (L/min) 44.4 ± 14.0 37.6 ± 13.7 .138
RER 1.1 ± 0.13 1.14 ± 0.08 .217
Note: Variables are expressed as the group mean ± standard deviation. Continuous P values are shown following inferential testing.
F IGURE 1 Cardiopulmonary exercise test data as a percentage of values predicted from normative data. * denotes a significant difference
between groups
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However, there was a difference in muscle function, with significantly
higher peak knee extensor and flexor isokinetic torque observed in
the CMT group (Table 1). The CMT group also walked significantly
faster over 10 m and covered a greater distance in 6 min (Table 1).
Physical activity monitoring revealed that the CMT group took signifi-
cantly more steps per day, but interestingly there were no differences
in total daily energy expenditure. There were no differences in time
spent in sedentary, moderate, or vigorous physical activity. Patient
reported outcome measures were comparable with no differences
between the groups.
4.3 | Associations with aerobic capacity (VO2
peak)
The disease severity measures for both conditions performed differ-
ently in the correlation analysis. In the group of participants with IBM,
the IBMFRS scale showed a moderate to strong correlation with VO2
peak but the same was not observed for the CMTES scale in the CMT
cohort (Table 3).
Exploratory correlation analysis between VO2 peak with body
structure and impairment variables for the CMT group revealed
significant, moderate relationships with three measures: body fat
percentage, FVC and peak isokinetic knee extensor torque (Table 3).
Multiple regression modelling showed no significant associations with
the three variables. FVC, then isokinetic knee extensor torque was
removed using a stepwise method. The final model showed body fat
percentage had low association with VO2 peak (Table 4).
For the IBM group, initial correlation analysis showed significant
relationships with the same three variables. FVC and peak knee exten-
sor torque were removed stepwise from the model due to weak
correlations leaving body fat percentage had a low association with
VO2 peak (Table 4).
Functional performance measures were explored associated with
VO2 peak in the same way. Initial correlation analysis for the CMT
group revealed relationships between VO2 peak and two functional
measures: 6-min walk test distance and the Walk-12 scale. Both vari-
ables were entered into the multiple regression model, and the Walk-
12 scale was removed stepwise due to weak correlation. Six-minute
walk test distance had a low association with VO2 peak (Table 4):
TABLE 3 Summary of univariate regression analysis with VO peak
IBM CMT




IBMFRS 0.756 .001a 0.467 0.911




BMI 0.302 .239 0.744 0.174 0.182 .419 0.570 0.223
Waist/hip ratio 0.020 .939 0.396 0.633 0.098 .664 0.287 0.523
Body fat % 0.568 .022a 0.841 0.086 0.606 .003a 0.795 0.377
FVC in sitting 0.486 .048 0.060 0.867 0.532 .011a 0.223 0.758
Resting heart rate 0.084 .749 0.420 0.539 0.077 .732 0.285 0.412
Resting SBP 0.460 .063 0.843 0.227 0.247 .268 0.172 0.719
Isokinetic knee extensor torque 0.520 .032a 0.266 0.732 0.501 .017a 0.128 0.721
Isokinetic knee flexor torque 0.646 .005a 0.422 0.867 0.473 .026 0.066 0.761
Fatigue severity scale 0.289 .260 0.717 0.188 0.187 .404 0.617 0.317
VAS for pain 0.249 .335 0.710 0.331 0.439 .041 0.759 0.042
Functional
activities
10-meter-walk time 0.611 .009 0.554 0.004 0.290 .190 0.568 0.008
6-min-walk distance 0.776 .001a 0.344 0.777 0.581 .005a 0.331 0.782
Total energy expenditure per day 0.372 .142 0.140 0.545 0.201 .369 0.162 0.553
Steps per day 0.657 .004a 0.186 0.367 0.092 .684 0.200 0.382
Average METs per day 0.641 .006a 0.099 0.652 0.312 .158 0.097 0.660
Physical activity duration per day 0.623 .008a 0.279 0.448 0.070 .758 0.292 0.428
Sedentary time 0.264 .306 0.644 0.128 0.181 .421 0.666 0.124
Walk-12 scale 0.607 .010a 0.862 0.269 0.573 .005a 0.779 0.189
IPAQ sitting time (min/day) 0.174 .505 0.643 0.381 0.051 .827 0.361 0.467
Falls self-efficacy scale 0.014 .957 0.496 0.472 0.372 .088 0.115 0.780
aSignificant correlations following modified Bonferroni adjustment. Pearson correlations were undertaken for continuous data and Spearman correlation
tests were undertaken for ordinal data.
Abbreviation: CI, confidence interval.
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For the IBM group, a larger number of functional variables were
identified in the initial correlation analysis: IBMFRS, 10 MTW time,
6-min walk distance, Walk-12, IPAQ, and average steps per day. The
following variables were removed stepwise from the model: Walk-12,
IPAQ, IBMFRS, 10 MTW time. The resulting model included 6-min
walk distance and average steps per day showing a strong association
with VO2 peak (Table 4):
5 | DISCUSSION
There are some similarities in performance between the two cohorts
but also some key differences that may help us understand the impact
of the presenting impairments on cardiorespiratory fitness.
When comparing the two conditions, both disease groups dem-
onstrated lower maximum heart rate, lower anaerobic threshold and
reduced VO2 peak variables compared to predicted norms. Partici-
pants with IBM showed even greater limitations than the CMT group
with the very low VO2 peak value of 14.3 ml/kg/min; this is particu-
larly notable when one considers that, a VO2 peak of 18 ml/min/kg is
deemed the minimum required for independent community living.24
The CMT group were younger, with less proximal muscle wasting,
which could have influenced the cycling task used for testing.
In healthy individuals, VO2 peak is considered to be limited by
central O2 delivery mechanisms, in particular due to the achievement
of maximal cardiac output.25 In this study, participants with CMT and
IBM terminated exercise with a reserve in heart rate (CMT, 76.1%;
IBM, 76.6%) and ventilation (CMT, 50.5%; IBM, 48.2%), indicating
central O2 delivery did not limit exercise. The low maximum values
for HR and ventilatory effort are unlikely due to early exercise cessa-
tion as patients exhibited high RER values, indicating high effort
levels.26 These two conditions do not have cardiac dysfunction as a
presenting symptom so chronotropic incompetence is unlikely, there-
fore, the attainment of VO2 peak in our cohorts appears largely due
to peripheral limiting factors.
The exercise test protocol in this study used a bicycle ergometer
that requires activity of the knee extensors and flexors in the most
part. It is reported in MRI studies that knee extensor function is
altered in both CMT and IBM.27 In people with IBM this is due to pri-
mary atrophy and fat infiltration. Weakness of the quadriceps is a pri-
mary presentation so if individuals are weaker to start with, they may
reach thresholds of function earlier, even if they are fatiguing at a nor-
mal rate. No previous work has been published exploring peripheral
fatiguability of muscle in people with IBM.
The same MRI study showed more general loss of thigh muscle vol-
ume in the cohort of people with CMT that was thought to represent
secondary disuse atrophy.27 Previous studies using stimulation to explore
fatigue in people with CMT demonstrate increased central activation fail-
ure.28 Another study found normal fatigue rate, but people with CMT
demonstrated lower activation initially, possibly due to central activation
failure.29 More recently, increased compensatory central activation in the
prefrontal cortex has been observed during a fatiguing task.30 The same
group also observed impaired neuromuscular recovery from fatigue in
CMT1A. These studies are in small cohorts, but there is an implication
that central activation influences task fatigue in people with CMT. This
may explain the early cessation during CPET testing observed.
The regression analysis demonstrated that body fat percentage in
both conditions was associated with aerobic capacity. A negative rela-
tionship between VO2 max and body fat percentage has been
observed in younger, healthy populations,31 so this may also be an
influence in this study but the direction of causality is not clear. Body
weight also forms part of the calculation for VO2 peak so could
increase the likelihood of association, but weight does not automati-
cally imply adiposity and is further complicated in muscle wasting dis-
eases. In addition, body mass index (BMI) was not associated with
VO2 peak in this cohort. The R
2 values were relatively low, however,
implying that other factors that were not measured in this study could
have greater associations with aerobic capacity.
Functional predictors of aerobic capacity are useful to ascertain
as they may be potential surrogate measures where CPET testing is
TABLE 4 Summary of multivariate regression models
Condition R2 Variable Coefficient
Standard
error P-Value Lower CI Upper CI
Associations of body structure
and impairment measures
IBM 0.323 Body fat percentage 0.358 0.138 .022 0.645 0.061
Constant 23.249 3.42 .0001 15.913 30.584
CMT 0.367 Body fat percentage 0.491 0.144 .003 0.791 0.19
Constant 34.075 3.75 .0001 26.252 41.897
Associations of functional
measures with VO2 peak
IBM 0.717 6-min walk distance 0.021 0.006 .002 0.009 0.033
Steps per day 0.0004 0.00017 .031 0.0004 0.0007
Constant 6.079 1.534 .001 2.787 9.369
CMT 0.338 6-min walk distance 0.0338 0.011 .005 0.012 0.056
Constant 8.773 4.094 .045 0.233 17.313
Note: Model 1: associations between body structure and impairment variables and VO2 peak. Model 2: associations between functional
measures and VO2 peak.
Abbreviation: CI, confidence interval.
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not available or indicated in an individual. Six-minute timed walk was
predictive of VO2 peak in both exercise groups and is a simple clini-
cal test to administer. The IBM participants also demonstrated that
steps per day were associated. Steps per day give an indication of
physical activity levels in this ambulant group and may represent
the impact of deconditioning through sedentary behavior. The
same relationship was not seen in the CMT participants, but there
was greater variability in steps per day as evidenced by the very
high standard deviation.
It is important to acknowledge the limitations of this study. We
made comparisons with normative data from upright bicycle
ergometry and participants in this study were in a semi-recumbent
position. The literature in non-neurological cohorts indicates no signif-
icant difference in VO2 peak between upright and semi-recumbent
cycling position of 65, comparable to the cycling position in this
study.32 This has not been tested in people with neuromuscular
diseases.
Participants were able to ambulate, so we did not have an oppor-
tunity to explore cardiorespiratory fitness in more severe disease
and/or at later stages due to the inclusion criteria for the main inter-
vention study, that may have also introduced recruitment bias. This
will be impacted by the small sample size. Recruitment of people with
rare diseases is difficult, and small samples are common in trials, but
the bias to more able individuals will influence how representative the
participants were of the population.
6 | CONCLUSIONS
This study explores performance of CPET testing in two neuromuscu-
lar diseases and factors that may relate to performance. Maximum
heart rate was not reached by the participant groups at peak oxygen
uptake indicating that peripheral factors, such as muscle atrophy, may
have limited performance. Peak oxygen uptake was predicted by body
fat percentage in both groups. Performance of the 6-min walk test
was also associated and could be recommended as a surrogate mea-
sure in the clinic.
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